Community Forum

Built enough weekend robot arms to be allergic to the 'robots are coming' hype reel. But something shifted in 2026, and it isn't a viral clip. Agility's Digit has moved 100k+ totes in a…

I read ops dashboards for a living, so here's what I check before backing anyone here, and none of it is revenue: 1) Shipping cadence: anything user-visible in the last three weeks? 2) Support…

Rules: real client project (with permission), agent does the first pass, I review everything. Wins: it cleared 14 tickets of the boring kind (prop drilling cleanup, a11y labels, dead CSS) in the time I…

Everyone debates whether UBI is affordable. Almost nobody asks how you'd actually PAY billions of people every month. As a fintech PM this is the part that keeps me up: identity (who gets it,…

Side project turned obsession: same non-trivial coding task (build a rate limiter with tests, from a fixed spec), five different models, every Friday, four weeks. Results: the top two swapped places twice, the "best"…

Nanotech has a branding problem — people imagine grey-goo nanobots. The reality is less cinematic and more useful: nanostructured electrodes for batteries, targeted drug delivery, water filtration, better solar. I work on the battery…

I've backed 30+ startups as an angel. What grabbed me about MeWeBe is the inversion: instead of a few rich people backing founders, a whole community stakes together and shares the upside. If even…

Raising for a climate hardware startup taught me: money is the easy part. What I actually want from backers is belief that shows up — intros, feedback, sharing our launches, voting in our favour.…

Everyone wants viral loops; nobody wants to fix the boring first five minutes. But onboarding is where you lose most users, silently. My rules: one obvious next action per screen, show value before asking…

Everyone wants a date, so here's mine with the caveat that timelines are mostly vibes: ~30% chance of something most experts would call AGI by 2032, ~60% by 2040. The bottleneck isn't raw capability…

We now have approved CRISPR therapies for sickle cell. That's astonishing and barely made the news. Somatic editing — fixing cells in a living patient — is here and accelerating. Germline editing (heritable changes…

This is the whole ballgame. Options, roughly best to worst in my view: (1) automation/AI dividends — tax the productivity gains that displace labour; (2) data dividends — you're the product, get paid; (3)…

Three months of testing how to become a source for AI answers. What moves the needle: (1) answer the question in the first two sentences — LLMs lift those; (2) use clear headers framed…

Three labs have a real shot, plus a Chinese lab people aren't watching closely enough, plus the chance it leaks out of open-source. But "first" may matter less than "safest and most deployed". Getting…

Both my SaaS products were embarrassing at launch. Both found their first users anyway, because the users cared about the problem, not the polish. Building in public forced me to ship weekly and the…